New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Research output: Contribution to journalJournal articleResearchpeer-review

Morten Persson, Palle Rasmussen, Jacob Madsen, Michael Ploug, Andreas Kjaer

The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.
Original languageEnglish
JournalNuclear Medicine and Biology
Issue number7
Pages (from-to)962-9
Number of pages8
Publication statusPublished - Oct 2012

    Research areas

  • Animals, Beta Particles, Cell Transformation, Neoplastic, Colorectal Neoplasms, Dideoxynucleosides, Female, HT29 Cells, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Mice, Molecular Targeted Therapy, Neoplasm Invasiveness, Oligopeptides, Positron-Emission Tomography, Radioisotopes, Receptors, Urokinase Plasminogen Activator, Substrate Specificity

ID: 45945376